Need Help?
Copied to clipboard!

A Phase III Randomized Double-Blinded Study Comparing the Combination of the BRAF Inhibitor Dabrafenib and the MEK Inhibitor Trametinib to Dabrafenib and Placebo as First-Line Therapy in Subjects with Unresectable (Stage IIIC) or Metastatic (Stage IV) Melanoma

Design and Aims: This study investigated baseline tumor genomic and immune features associated with durable response to BRAF-targeted therapy in BRAF-mutant metastatic melanoma, where most patients who initially respond eventually progress but a subset derives durable benefit.

Population Information: We analyzed pretreatment tumor samples from a clinically annotated cohort of 155 patients with BRAF-mutant metastatic melanoma treated with first-line BRAF/MEK inhibition in the COMBI-d trial and followed for up to five years, classifying patients as durable responders (progression-free survival ≥24 months) or rapid progressors (progression-free survival <6 months with progression).

Molecular Technologies Employed: Whole-exome sequencing of paired pretreatment tumor and normal samples was performed to derive genomic features, and spatial immunohistochemistry characterized the tumor immune microenvironment in a subset of samples.

Principal Findings: A global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished durable responders from rapid progressors; combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase or radiographic lesion dimensions) enabled a parsimonious predictive model of durable response with high precision and specificity. These predictors did not identify durable responders among an analogous population treated with immunotherapy instead, suggesting they are specific to targeted therapy. High intratumoral, but not peritumoral, CD8+ T-cell infiltration was additionally associated with prolonged survival on BRAF-targeted therapy.

Data Available through dbGaP: Data available through dbGaP include whole-exome sequencing (BAM files) from paired pretreatment tumor and normal samples, along with corresponding clinical and outcome phenotype data.